S. YARAŞ Et Al. , "The efficacy and tolerability of Glecaprevir/Pibrentasvir treatment in a real-world Chronic Hepatitis C patients cohort," AASLD TASL Hepatology Connect Meeting, 2023 , Ankara, Turkey, 2023
YARAŞ, S. Et Al. 2023. The efficacy and tolerability of Glecaprevir/Pibrentasvir treatment in a real-world Chronic Hepatitis C patients cohort. AASLD TASL Hepatology Connect Meeting, 2023 , (Ankara, Turkey).
YARAŞ, S., DEMİR, M., BARUTÇU, S., YILDIRIM, A. E., GÜREL, S., ÜÇBİLEK, E., ... KURTULMUŞ, İ. A.(2023). The efficacy and tolerability of Glecaprevir/Pibrentasvir treatment in a real-world Chronic Hepatitis C patients cohort . AASLD TASL Hepatology Connect Meeting, 2023, Ankara, Turkey
YARAŞ, SERKAN Et Al. "The efficacy and tolerability of Glecaprevir/Pibrentasvir treatment in a real-world Chronic Hepatitis C patients cohort," AASLD TASL Hepatology Connect Meeting, 2023, Ankara, Turkey, 2023
YARAŞ, SERKAN Et Al. "The efficacy and tolerability of Glecaprevir/Pibrentasvir treatment in a real-world Chronic Hepatitis C patients cohort." AASLD TASL Hepatology Connect Meeting, 2023 , Ankara, Turkey, 2023
YARAŞ, S. Et Al. (2023) . "The efficacy and tolerability of Glecaprevir/Pibrentasvir treatment in a real-world Chronic Hepatitis C patients cohort." AASLD TASL Hepatology Connect Meeting, 2023 , Ankara, Turkey.
@conferencepaper{conferencepaper, author={SERKAN YARAŞ Et Al. }, title={The efficacy and tolerability of Glecaprevir/Pibrentasvir treatment in a real-world Chronic Hepatitis C patients cohort}, congress name={AASLD TASL Hepatology Connect Meeting, 2023}, city={Ankara}, country={Turkey}, year={2023}}